Navigation Links
La Jolla Institute continues longtime collaboration with Kyowa Hakko Kirin California
Date:7/30/2013

SAN DIEGO (July 30, 2013) La Jolla Institute for Allergy and Immunology and Kyowa Hakko Kirin California, Inc. (KKC), a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (KHK) , a global specialty pharmaceutical company, today announced the signing of a new agreement that marks another milestone in one of the most enduring industry-academic collaborations in the world.

The six-year agreement continues a research alliance spanning more than two decades between La Jolla Institute, an academic nonprofit and a world leader in immunology research, and KKC, one of Kyowa Hakko Kirin's research and development centers in the United States. The collaboration leverages the pharmaceutical company's discovery and development capabilities and La Jolla Institute's expertise in basic research to accelerate translation of research discoveries into potential new treatments.

Under the terms of the agreement, La Jolla Institute will receive a combination of discretionary research funding, and funds dedicated to specific projects to be selected by a steering committee of La Jolla Institute and Kyowa Hakko Kirin leaders. The research funding agreement will span through the end of 2018. Kyowa Hakko Kirin California will receive first rights of negotiation to pursue translation of La Jolla Institute discoveries, stemming from research projects funded by KKC.

La Jolla Institute Chief Business Officer Patrick Ho says the agreement is a win-win for both parties. "La Jolla Institute benefits from the added funding to support research that may eventually make its way into KHK's pharmaceutical research and development pipeline," says Ho. "No doubt this collaboration is exceptional and stands apart among the Institute's agreements with pharmaceutical companies."

Mitchell Kronenberg, Ph.D., La Jolla Institute president & chief scientific officer, says the contract "continues the long tradition of scientific excellence and mutual respect that has existed between our two organizations for the last 25 years."

Hiroshi Yano, Ph.D., the newly-appointed KKC president, says the agreement will further enhance the longstanding relationship. "While the investment efficiency of drug discovery and development is challenging for the pharmaceutical industry, this new agreement enables closer collaboration that will allow KKC and the La Jolla Institute to greatly enhance target identification and drug discovery efforts," says Dr. Yano. He notes that the new agreement structure, involving a joint steering committee for project selection, is "only achievable based on our mutual understanding and history. I appreciate the culture built by our predecessors."

La Jolla Institute Board Member David Webb, Ph.D., a scientist and biotech industry veteran, notes that the partnership is beneficial for everyone involved, most importantly for the millions of people worldwide who are desperately in need of new and better treatments for disease. "Collaborations between research centers like La Jolla Institute and pharmaceutical companies such as KHK create a bridge that propels major discoveries from the laboratory into drug development and ultimately into the hands of people suffering from disease," says Dr. Webb, chairman emeritus of Biocom, the San Diego-based life science industry trade association.

Dr. Yano expects new synergies to be created between KKC and the La Jolla Institute. "We have already seen that the science of the La Jolla Institute is advancing drug discovery in KKC, and I hope that KKC's drug discovery expertise will also help foster continued scientific breakthroughs at the Institute. My hope is that this virtuous cycle leads to improved human health worldwide."

Reflecting this goal, several La Jolla Institute discoveries are advancing toward becoming new treatments for debilitating disorders including psoriasis, inflammatory bowel disease and rheumatoid arthritis, thanks to the partnership. Several of these potential therapies, including a drug that eases immune rejection problems in patients following organ transplantation, are in phase II clinical human studies, with others at various stages of development.

Dr. Kronenberg notes that academic-industry relationships are critical to advance the true mission of nonprofit academic research institutes. "Our ultimate goal is to see our findings put into direct use for improving human health," he notes. "It's the reason we exist." However, most research institutes aren't equipped for clinical trials and other aspects of drug development, which underscores the need for relationships between research nonprofits and pharmaceutical companies.

"KHK has the kind of long-term commitment that is necessary to take discoveries from the bench, into human clinical studies, and, if successful, into approved drugs," he says. "It's a complementary process without which many important breakthroughs might never get beyond the laboratory stage."

While research agreements between academic institutions and pharmaceutical companies are commonplace today, the collaboration between KKC and La Jolla Institute dates back to the Institute's founding in 1988, at a time when such arrangements were quite rare. "Our institute was fortunate to have been founded by a group of individuals with incredible vision and foresight about the necessity for strong linkages between academia and the pharmaceutical industry," says Dr. Kronenberg. "Back then it was a very novel even controversial idea."

"Their wisdom has proven extremely accurate," he adds. "Today such arrangements are a pivotal piece of drug discovery efforts throughout this country."


'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Related biology news :

1. La Jolla Institute discovery could lead to new way to screen drugs for adverse reactions
2. La Jolla Institute scientist discovers key step in immune system-fueled inflammation
3. La Jolla institute identifies critical cell in fighting E. coli infection
4. La Jolla Institute identifies molecular switch enabling immune cells to better fight disease
5. La Jolla Institute discovers new player critical to unleashing T cells against disease
6. Diabetes Research Institute develops oxygen-generating biomaterial
7. Space research institute honors Sen. Hutchison with Pioneer Award
8. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
9. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
10. Cary Institute Hydrofracking Forum
11. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... is apparently one of the most popular hubs ... Project, MetaHIT and other huge studies of human ... that past few years, the microbiome space has ... applied biomedical research. This report focuses on ...
(Date:2/3/2016)... --> --> ... Fingerprint Identification System Market by Component (Hardware and Software), ... Finance, Government, Healthcare, and Transportation) and Geography - Global ... expected to be worth USD 8.49 Billion by 2020 ... 2020. The transformation and technology evolution from the manual ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... DURHAM, N.C. , Feb. 8, 2016 Novan, Inc. ... named Chairman of the Board of Directors of Novan. In addition, ... Directors. North Carolina . ... The Company also announced that it received a total of $32.8 ... December 2015 from its private investor network originating throughout the Research ...
(Date:2/8/2016)... , Feb. 8, 2016  BioElectronics Corporation ... medical devices, announced today that it is responding ... proceedings from the Securities and Exchange Commission posted ... Staelin , Chairman of the Board of BioElectronics ... of Business Administration at The Fuqua School of ...
(Date:2/8/2016)... ... ... Bulk food product inspection systems are specifically designed to ... production process. Despite frequently inspecting loose product prior to packaging, product inspection systems ... of dry powders. , Mettler-Toledo Product Inspection's brand-new white paper entitled "Improving Food ...
(Date:2/8/2016)... (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, ... present information about the company,s programs at the BIOCEO conference today ... City . --> --> ... Registered attendees can request a one on one meeting through the conference ... --> New York City . --> ...
Breaking Biology Technology: